scholarly journals A novel approach to regenerate bone loss in an adolescent using concentrated growth factors: One-year follow-up

2020 ◽  
Vol 9 (1) ◽  
pp. 428
Author(s):  
MebinGeorge Mathew ◽  
AshuJagdish Soni ◽  
MdMuzammil Khan ◽  
Afreen Kauser
Keyword(s):  
Growth Factors ◽  
Bone Loss ◽  
Novel Approach ◽  
Concentrated Growth Factors ◽  
One Year

Prevention of early postmenopausal bone loss by risedronate: One year follow-up data

Bone ◽  
1995 ◽  
Vol 17 (6) ◽  
pp. 607 ◽  
Author(s):  
L. Mortensen ◽  
P. Bekker ◽  
J. DiGennaro ◽  
D. Axelrod ◽  
P. Charles ◽  
...  
Keyword(s):  
Bone Loss ◽  
Postmenopausal Bone Loss ◽  
One Year ◽  
Early Postmenopausal Bone Loss

scholarly journals Brief Intermittent Neuroleptic Prophylaxis for Selected Schizophrenic Out-patients

1989 ◽  
Vol 155 (05) ◽  
pp. 702-706 ◽  
Author(s):  
H. A. McClelland ◽  
G. Harrison ◽  
S. D. Soni
Keyword(s):  
Psychotic Symptoms ◽  
Intermittent Treatment ◽  
Double Blind ◽  
Prodromal Symptoms ◽  
Novel Approach ◽  
Depot Neuroleptic ◽  
One Year ◽  
Depot Injections ◽  
To Receive

“A study was conducted to investigate a novel approach to the prophylaxis of schizophrenic relapse. The treatment strategy comprised brief intermittent courses of neuroleptic agents begun as soon as non-psychotic symptoms believed to be early signs of relapse appeared. Fifty four stable, remitted outpatients meeting the American Psychiatric Association's DSM–III criteria for schizophrenia were randomised double blind to receive brief intermittent treatment with either active or placebo depot neuroleptic injections. Only three patients given placebo injections and two controls were admitted to hospital during one year of follow up. Eight (30%) of the patients given placebo injections and only 2 (7%) of the controls, however, had a recurrence of schizophrenic symptoms. Patients given placebo injections experienced fewer extrapyramidal side effects and showed a trend towards a reduction in tardive dyskinesia. Dysphoric and neurotic symptoms were identified before eight out of 11 relapses, and these symptoms were more frequent in patients given placebo depot injections. These results suggest a viable but not necessarily better alternative to continuous oral or depot treatment for less ill, chronic, stabilised schizophrenics based on the early treatment of putative prodromal symptoms of relapse.”

scholarly journals Brief Intermittent Neuroleptic Prophylaxis for Selected Schizophrenic Out-patients

1989 ◽  
Vol 155 (5) ◽  
pp. 702-706
Author(s):  
H. A. McClelland ◽  
G. Harrison ◽  
S. D. Soni
Keyword(s):  
Psychotic Symptoms ◽  
Intermittent Treatment ◽  
Double Blind ◽  
Prodromal Symptoms ◽  
Novel Approach ◽  
Depot Neuroleptic ◽  
One Year ◽  
Depot Injections ◽  
To Receive

“A study was conducted to investigate a novel approach to the prophylaxis of schizophrenic relapse. The treatment strategy comprised brief intermittent courses of neuroleptic agents begun as soon as non-psychotic symptoms believed to be early signs of relapse appeared. Fifty four stable, remitted outpatients meeting the American Psychiatric Association's DSM–III criteria for schizophrenia were randomised double blind to receive brief intermittent treatment with either active or placebo depot neuroleptic injections. Only three patients given placebo injections and two controls were admitted to hospital during one year of follow up. Eight (30%) of the patients given placebo injections and only 2 (7%) of the controls, however, had a recurrence of schizophrenic symptoms. Patients given placebo injections experienced fewer extrapyramidal side effects and showed a trend towards a reduction in tardive dyskinesia. Dysphoric and neurotic symptoms were identified before eight out of 11 relapses, and these symptoms were more frequent in patients given placebo depot injections. These results suggest a viable but not necessarily better alternative to continuous oral or depot treatment for less ill, chronic, stabilised schizophrenics based on the early treatment of putative prodromal symptoms of relapse.”

Significant Bone Loss in Obese Patients with Acanthosis Nigricans after LSG—One-Year Follow-Up Study

Diabetes ◽  
2018 ◽  
Vol 67 (Supplement 1) ◽  
pp. 2062-P
Author(s):  
YOUYANG ZHANG ◽  
ZHIYIN ZHANG ◽  
CUILING ZHU ◽  
SIQI SUN ◽  
YING YIN ◽  
...  
Keyword(s):  
Bone Loss ◽  
Acanthosis Nigricans ◽  
Obese Patients ◽  
Follow Up Study ◽  
One Year

scholarly journals A One-year Follow-up Study of a Tapered Hydrophilic Implant Design Using Various Placement Protocols in the Maxilla

2016 ◽  
Vol 10 (1) ◽  
pp. 680-691 ◽  
Author(s):  
Jakob Zwaan ◽  
Leonardo Vanden Bogaerde ◽  
Herman Sahlin ◽  
Lars Sennerby
Keyword(s):  
Survival Rate ◽  
Bone Loss ◽  
Implant Design ◽  
Insertion Torque ◽  
Daily Routine ◽  
High Survival ◽  
Marginal Bone Loss ◽  
The Mean ◽  
One Year

Purpose: To study the clinical/radiographic outcomes and stability of a tapered implant design with a hydrophilic surface when placed in the maxilla using various protocols and followed for one year. Methods: Ninety-seven consecutive patients treated as part of daily routine in two clinics with 163 tapered implants in healed sites, in extraction sockets and together with bone augmentation procedures in the maxilla were evaluated after one year in function. Individual healing periods varying from 0 to 6 months had been used. Insertion torque (IT) and resonance frequency analysis (RFA) measurements were made at baseline. Follow-up RFA registrations were made after 6 and 12 months of loading. The marginal bone levels were measured in intraoral radiographs from baseline and after 12 months. A reference group consisting of 163 consecutive straight maxillary implants was used for the comparison of baseline IT and RFA measurements. Results: Five implants failed before loading, giving an implant survival rate of 96.9% and a prosthesis survival rate of 99.4% after one year. The mean marginal bone loss after one year was 0.5 mm (SD 0.4). The mean IT was statistically significantly higher for tapered than for straight reference implants (41.3 ± 12.0 Ncm vs 33.6 ± 12.5 Ncm, p < 0.001). The tapered implants showed a statistically insignificantly higher mean ISQ value than the straight references implants (73.7 ± 6.4 ISQ vs 72.2 ± 8.0 ISQ, p=0.119). There was no correlation between IT and marginal bone loss. There was a correlation between IT and RFA measurements (p < 0.001). Conclusion: The tapered implant showed a high survival rate and minimal marginal bone loss after one year in function when using various protocols for placement. The tapered implant showed significantly higher insertion torque values than straight reference implants.

Influence of mini-implant length on crestal bone loss: A one-year follow-up

2012 ◽  
Vol 2 (2) ◽  
pp. 79
Author(s):  
MuhammadH Alharissy ◽  
ReddaH Alharissy ◽  
SuleimanT Dayoub
Keyword(s):  
Bone Loss ◽  
Crestal Bone Loss ◽  
One Year ◽  
Implant Length

scholarly journals Concentrated Growth Factors as an Ingenious Biomaterial in Regeneration of Bony Defects after Periapical Surgery: A Report of Two Cases

2019 ◽  
Vol 2019 ◽  
pp. 1-6 ◽  
Author(s):  
Nivedhitha Malli Sureshbabu ◽  
Kathiravan Selvarasu ◽  
Jayanth Kumar V ◽  
Mahalakshmi Nandakumar ◽  
Deepak Selvam
Keyword(s):  
Growth Factors ◽  
Bone Regeneration ◽  
Healing Time ◽  
Platelet Concentrates ◽  
Periapical Lesions ◽  
New Family ◽  
Retrograde Filling ◽  
Concentrated Growth Factors ◽  
Autologous Platelet

The overall success of a periapical surgery is assessed in terms of regeneration of functional periradicular tissues. The regenerative potential of platelets has been well documented. This article describes the use of concentrated growth factors (CGF), a new family of autologous platelet concentrates, as a sole material for bone regeneration after periapical surgery. 32- and 35-year-old female patients diagnosed with Ellis Class IV, an open apex in 11 with apical periodontitis in 11 and 12 and previously root canal-treated 31 and 41 with a chronic apical abscess, respectively, were managed with endodontic surgery. Subsequent to apicectomy and retrograde filling, the CGF fibrin block and membrane were used before suturing. There was uneventful healing during the immediate post-op and the subsequent follow-up periods. CGF is produced by a differential centrifugation process that results in the formation of a denser fibrin matrix richer in growth factors than those observed in PRF. Reasonable osseous healing was seen as early as 6-month follow-up, thereby recommending the use of CGF as an alternative to bone grafts and membranes in extensive periapical lesions to enhance bone regeneration and to decrease the healing time.

Recovery of muscle atrophy and bone loss from 90 days bed rest: Results from a one-year follow-up

Bone ◽  
2009 ◽  
Vol 44 (2) ◽  
pp. 214-224 ◽  
Author(s):  
J. Rittweger ◽  
D. Felsenberg
Keyword(s):  
Bone Loss ◽  
Muscle Atrophy ◽  
Bed Rest ◽  
One Year
Sign in / Sign up

Export Citation Format

Share Document